GlobalData on MSN6d
AbbVie and Neomorph link on oncology/immunology glue degraders
AbbVie and Neomorph are forming a partnership and option-to-license agreement to develop molecular glue degraders, aiming to ...
Pharm Exec6d
AbbVie, Neomorph Strike Deal to Co-Develop Molecular Glue Degraders for Oncology, Immunology
Under terms of the deal, AbbVie will provide Neomorph with an upfront payment and the potential to earn up to $1.64 billion ...
Zacks.com on MSN6d
AbbVie Inks a Deal With Neomorph for Molecular Glue Degraders
Per the terms of the deal, AbbVie will use Neomorph's proprietary platform to develop novel drugs targeting oncology and ...
PMLiVE6d
AbbVie and Neomorph enter molecular glue degrader partnership worth $1.64bn
AbbVie has partnered with Neomorph to develop new molecular glue degraders (MGDs) for multiple targets across oncology and ...
Nasdaq6d
AbbVie Inks a Deal With Neomorph for Molecular Glue Degraders
AbbVie ABBV announced that it has entered into a collaboration and option-to-license agreement with the San Diego-based private biotech Neomorph to develop molecular glue degraders for multiple ...